Chong Kun Dang exports biosimilar referencing anemia treatment to Japanese branch

Published: 2018-04-17 21:57:00
Updated: 2018-04-17 21:58:39

Chong Kun Dang(CEO Young-Joo Kim) recently signed a business partnership agreement of ‘CKD-11101,’ a second-generation anemia treatment biosimilar, with a U.S. global pharmaceutical company’s Japanese branch. The agreement includes exportation of its finished drugs as well.

Under the agreement, ...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.